Ruth Holm Ph D
Research group leader
Division of Pathology
Rikshospitalet
Montebello
0310 Oslo
Norway
Office: + (47) 2293
Fax: + (47) 22508554
email: rut.holm@radiumhospitalet.no
Training:
Expertise:
In situ hybridization, Immunohistochemistry
Research Interests:
gynaecological cancers and cell cycle-, apoptosis- and cell
adhesion-markers, matrix metalloproteinases and HPV. I
Other Links:
Selected Publications:
Khouja MH, Baekelandt M, Nesland JM, Holm R.
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
Int J Gynecol Pathol. 2007 Oct;26(4):418-25
Holm R, Knopp S, Suo Z, Tropè C, Nesland JM.
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.
J Clin Pathol. 2007 Oct;60(10):1086-91. Epub 2006 Dec 8
Knopp S, Nesland JM, Tropé C, Holm R.
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
.Am J Clin Pathol. 2006 Aug;126(2):266-76.
Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R.
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
Am J Clin Pathol. 2005 Sep;124(3):392-401
Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R.
Cyclins D1, D3, E, and A in vulvar carcinoma patients.
Gynecol Oncol. 2005 Jun;97(3):733-9.
Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R.
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas.
Gynecol Oncol. 2004 Oct;95(1):37-45.
Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R.
E-cadherin and catenins in early squamous cervical carcinoma.
Gynecol Oncol. 2004 Aug;94(2):521-7
Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R.
Cyclins and proliferation markers in early squamous cervical carcinoma.
Gynecol Oncol. 2004 Jan;92(1):40-6.